BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 22949088)

  • 1. Pulmonary exacerbations in cystic fibrosis: young children with characteristic signs and symptoms.
    Regelmann WE; Schechter MS; Wagener JS; Morgan WJ; Pasta DJ; Elkin EP; Konstan MW;
    Pediatr Pulmonol; 2013 Jul; 48(7):649-57. PubMed ID: 22949088
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Chinese experts consensus statement: diagnosis and treatment of cystic fibrosis (2023)].
    ; ;
    Zhonghua Jie He He Hu Xi Za Zhi; 2023 Apr; 46(4):352-372. PubMed ID: 36990700
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibiotic treatment of signs and symptoms of pulmonary exacerbations: a comparison by care site.
    Schechter MS; Regelmann WE; Sawicki GS; Rasouliyan L; VanDevanter DR; Rosenfeld M; Pasta D; Morgan W; Konstan MW
    Pediatr Pulmonol; 2015 May; 50(5):431-40. PubMed ID: 25530325
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pulmonary outcome prediction (POP) tools for cystic fibrosis patients.
    VanDevanter DR; Wagener JS; Pasta DJ; Elkin E; Jacobs JR; Morgan WJ; Konstan MW
    Pediatr Pulmonol; 2010 Dec; 45(12):1156-66. PubMed ID: 20717915
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Course of Illness after Viral Infection in Indian Children with Cystic Fibrosis.
    Gulla KM; Balaji A; Mukherjee A; Jat KR; Sankar J; Lodha R; Kabra SK
    J Trop Pediatr; 2019 Apr; 65(2):176-182. PubMed ID: 29893951
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The clinical presentations of pulmonary aspergillosis in children with cystic fibrosis - preliminary report.
    Walicka-Serzysko K; Sands D
    Dev Period Med; 2015; 19(1):66-79. PubMed ID: 26003072
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pulmonary exacerbations in cystic fibrosis.
    Rabin HR; Butler SM; Wohl ME; Geller DE; Colin AA; Schidlow DV; Johnson CA; Konstan MW; Regelmann WE;
    Pediatr Pulmonol; 2004 May; 37(5):400-6. PubMed ID: 15095322
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lung clearance index to monitor treatment response in pulmonary exacerbations in preschool children with cystic fibrosis.
    Rayment JH; Stanojevic S; Davis SD; Retsch-Bogart G; Ratjen F
    Thorax; 2018 May; 73(5):451-458. PubMed ID: 29449440
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rhinovirus-associated pulmonary exacerbations show a lack of FEV1 improvement in children with cystic fibrosis.
    Cousin M; Molinari N; Foulongne V; Caimmi D; Vachier I; Abely M; Chiron R
    Influenza Other Respir Viruses; 2016 Mar; 10(2):109-12. PubMed ID: 26493783
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Approach to treating cystic fibrosis pulmonary exacerbations varies widely across US CF care centers.
    Kraynack NC; Gothard MD; Falletta LM; McBride JT
    Pediatr Pulmonol; 2011 Sep; 46(9):870-81. PubMed ID: 21465675
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral, inhaled, and intravenous antibiotic choice for treating pulmonary exacerbations in cystic fibrosis.
    Wagener JS; Rasouliyan L; VanDevanter DR; Pasta DJ; Regelmann WE; Morgan WJ; Konstan MW;
    Pediatr Pulmonol; 2013 Jul; 48(7):666-73. PubMed ID: 22888106
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibiotic duration and changes in FEV
    Espel JC; Palac HL; Cullina JF; Clarke AP; McColley SA; Prickett MH; Jain M
    BMC Pulm Med; 2017 Nov; 17(1):160. PubMed ID: 29187171
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk factors for onset of persistent respiratory symptoms in children with cystic fibrosis.
    McColley SA; Ren CL; Schechter MS; Regelmann WE; Pasta DJ; Konstan MW;
    Pediatr Pulmonol; 2012 Oct; 47(10):966-72. PubMed ID: 22359344
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact of respiratory tract infections on the nutritional state of children with cystic fibrosis.
    Trandafir LM; Moscalu M; Diaconu G; Cîrdeiu E; Tudose AA; Coman G; Păduraru DT
    Rev Med Chir Soc Med Nat Iasi; 2013; 117(4):863-9. PubMed ID: 24502062
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Standardized Treatment of Pulmonary Exacerbations (STOP) study: Observations at the initiation of intravenous antibiotics for cystic fibrosis pulmonary exacerbations.
    Sanders DB; Solomon GM; Beckett VV; West NE; Daines CL; Heltshe SL; VanDevanter DR; Spahr JE; Gibson RL; Nick JA; Marshall BC; Flume PA; Goss CH;
    J Cyst Fibros; 2017 Sep; 16(5):592-599. PubMed ID: 28460885
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Zinc Supplementation for One Year Among Children with Cystic Fibrosis Does Not Decrease Pulmonary Infection.
    Sharma G; Lodha R; Shastri S; Saini S; Kapil A; Singla M; Mukherjee A; Jat KR; Kabra M; Kabra SK
    Respir Care; 2016 Jan; 61(1):78-84. PubMed ID: 26443019
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Leukotriene receptor antagonists in children with cystic fibrosis lung disease : anti-inflammatory and clinical effects.
    Schmitt-Grohé S; Zielen S
    Paediatr Drugs; 2005; 7(6):353-63. PubMed ID: 16356023
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pulmonary exacerbations in CF patients with early lung disease.
    Anstead M; Saiman L; Mayer-Hamblett N; Lands LC; Kloster M; Goss CH; Rose L; Burns JL; Marshall B; Ratjen F
    J Cyst Fibros; 2014 Jan; 13(1):74-9. PubMed ID: 24029220
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pulmonary exacerbations in cystic fibrosis with negative bacterial cultures.
    Zemanick ET; Wagner BD; Harris JK; Wagener JS; Accurso FJ; Sagel SD
    Pediatr Pulmonol; 2010 Jun; 45(6):569-77. PubMed ID: 20503282
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of pseudomonas aeruginosa colonization on lung function and anthropometric variables in children with cystic fibrosis.
    Pamukcu A; Bush A; Buchdahl R
    Pediatr Pulmonol; 1995 Jan; 19(1):10-5. PubMed ID: 7675552
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.